Please login to the form below

Not currently logged in

Keryx Biopharmaceuticals

This page shows the latest Keryx Biopharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Keryx Biopharmaceuticals' Fexeric approved in EU

Keryx Biopharmaceuticals' Fexeric approved in EU

New treatment option for chronic kidney disease. Keryx Biopharmaceuticals' Fexeric has been approved in Europe as a treatment for controlling phosphorus levels in adults with chronic kidney disease. ... Greg Madison, CEO at Keryx Biopharmaceuticals, said:

Latest news

  • Aeterna Zentaris under the cosh as myeloma candidate fails

    That result prompted the US developer of the drug, Keryx Biopharmaceuticals, to return rights to Aeterna Zentaris, which is also exploring the activity of perifosine in renal cell carcinoma, non-small

  • Extending the arsenal

    Introducing perifosine. Perifosine is a small-molecule compound that was originally discovered by Zentaris (now AEterna Zentaris) and has since been licensed to Keryx Biopharmaceuticals in the US, Canada and Mexico,

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....